SecBot SecBot
Biotech Drug Report Generated Jul 6, 2026

Ordspono

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (EU), Phase 3 ongoing globally
Time to market
Approved in EU (Aug 2024) and launching commercially; US timeline unknown after two CRLs
Why 4/10
Ordspono is already approved and launching in the EU (since Aug 2024) with no pending US FDA catalyst. Two CRLs were issued (most recently Aug 2025, on manufacturing site issues) and no third resubmission has been announced. The next potential triggers are ongoing Phase 3 Olympia readouts, but none have a firm dated binary within ~12 months. Even if successful, Ordspono is a small program within Regeneron's diversified portfolio (Dupixent alone >$17B/yr).
Actionable Insight NEUTRAL

For REGN investors, Ordspono is a non-binary minor commercial asset. The EU launch is underway but sales are small relative to Regeneron's scale. The US path is unclear after two FDA rejections (enrollment timelines, then manufacturing). Watch for: (1) any announcement of a third BLA resubmission, (2) Olympia-3 Part 1B data at ASCO/ASH, and (3) whether EU conditional marketing renewal faces any hurdles.

Price Chart

Loading chart...

Executive Summary

Ordspono (odronextamab) is Regeneron's first approved bispecific antibody, cleared in the EU in August 2024 for two types of relapsed/refractory B-cell lymphoma (FL and DLBCL) after prior therapies. It works by bridging cancer cells to immune T-cells. The US path has been rocky, the FDA has rejected it twice (first on confirmatory trial enrollment, then on a third-party manufacturer site inspection). Phase 3 Olympia studies are ongoing globally, with early data in first-line DLBCL looking promising. For Regeneron (a ~$65B market cap biotech with blockbuster Dupixent), Ordspono is a modest commercial contributor, not a needle-mover. GlobalData projects ~$569M peak sales by 2030.

How It Works

Ordspono is a bispecific antibody, a Y-shaped protein engineered to grab two things at once. One arm latches onto CD20, a protein found on the surface of cancerous B-cells (a type of white blood cell). The other arm grabs CD3, found on the patient's own T-cells ("killer" immune cells). By bridging the cancer cell to the T-cell, it tricks the immune system into attacking and destroying the lymphoma.

Trial Status

Approved in the EU since Aug 2024 for relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) after 2+ prior lines. Phase 3 Olympia program is actively enrolling/testing across multiple studies: Olympia-1/2/5 in FL, Olympia-3 in first-line DLBCL (combo with CHOP). Olympia-3 Part 1B results presented at ASCO 2026 showed promising efficacy. A Phase 2 ELM-2 study is active but no longer recruiting (est. primary completion Jul 2026). In the US, the FDA has issued two CRLs, first in Mar 2024 (confirmatory trial enrollment), second in Aug 2025 (Catalent manufacturing site inspection), with no announced resubmission plan.

The Two-Sided Case

▲ Bull Case4
First-in-class approval in EU validates the drug's efficacy and safety profile, Phase 2 data showed 80.5% overall response rate and 74.2% complete response rate in FL (source: LinkedIn/EHA2025 post citing Phase II results).
Olympia-3 Phase 3 data in first-line DLBCL (combo with CHOP chemo) has shown promising early efficacy with durable responses, potentially opening a much larger market beyond the current r/r label (source: ASCO 2026 abstract via ascopubs.org).
GlobalData analyst consensus forecasts $569M in total global sales by 2030, a meaningful commercial asset for Regeneron's oncology pipeline (source: Pharmaceutical Technology).
Both FDA CRLs were for non-clinical issues (enrollment timelines and manufacturing site inspection), not safety or efficacy, suggesting the drug itself is approvable once logistics are resolved (source: Pharm Exec).
▼ Bear Case4
FDA has rejected the drug twice, in Mar 2024 (confirmatory trial enrollment) and Aug 2025 (Catalent manufacturing site inspection), with no announced plan for a third resubmission, making US commercialization timeline highly uncertain (source: Cancer Network).
Intensely competitive market: Roche's Lunsumio (mosunetuzumab) and Columvi (glofitamab) plus AbbVie/Genmab's Epkinly (epcoritamab) are already approved in both the US and EU for similar lymphoma indications (source: BioPharma Dive).
Ordspono is a small contributor for Regeneron, the company's Q1 2026 revenue was $3.6B driven primarily by Dupixent ($4.34B/qtr global sales recorded by Sanofi) and Eylea. Even $569M peak sales would be <4% of total revenue (source: Regeneron Q1 2026 earnings via Finviz).
A quality-related lot recall of Ordspono 80mg occurred in Jan 2026 in Germany due to vial closure integrity issues, potentially denting prescriber confidence in the EU launch (source: Gelbe Liste).

Upcoming Catalysts

  • Olympia-3 Part 1B randomized data readout (Phase 3 frontline DLBCL), further presentations likely at ASH 2026
  • Olympia-1 and Olympia-2 Phase 3 enrollment completion updates for r/r FL
  • Any announcement of a third US FDA BLA resubmission and timeline
  • EU conditional marketing authorization annual renewal process
  • Commercial launch revenue updates in Regeneron quarterly earnings calls

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 16

Hover a chip for the title
1 en.wikipedia.org2 ema.europa.eu3 biopharmadive.com4 targetedonc.com5 onclive.com6 targetedonc.com7 cancernetwork.com8 pharmexec.com9 pharmaceutical-technology.com10 druganalyst.com11 biospace.com12 link.springer.com13 ascopubs.org14 targetedonc.com15 gelbe-liste.de16 finviz.com